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Abstract 
Background: Traditionally, it has taken decades to introduce new interventions in low-income countries. Several 
factors account for these delays, one of which is the absence of a framework to facilitate comprehensive understand-
ing of policy process to inform policy makers and stimulate the decision-making process. In the case of the proposed 
introduction of malaria vaccines in Tanzania, a specific framework for decision-making will speed up the administra-
tive process and shorten the time until the vaccine is made available to the target population.
Methods: Qualitative research was used as a basis for developing the Policy Framework. Interviews were conducted 
with government officials, bilateral and multilateral partners and other stakeholders in Tanzania to assess malaria 
treatment policy changes and to draw lessons for malaria vaccine adoption.
Results: The decision-making process for adopting malaria interventions and new vaccines in general takes years, 
involving several processes: meetings and presentations of scientific data from different studies with consistent 
results, packaging and disseminating evidence and getting approval for use by the Ministry of Health and Social 
Welfare (MOHSW). It is influenced by contextual factors; Promoting factors include; epidemiological and intervention 
characteristics, country experiences of malaria treatment policy change, presentation and dissemination of evidence, 
coordination and harmonization of the process, use of international scientific evidence. Barriers factors includes; 
financial sustainability, competing health and other priorities, political will and bureaucratic procedures, costs related 
to the adoption and implementations of interventions, supply and distribution and professional compliance with 
anti-malarial drugs.
Conclusion: The framework facilitates the synthesis of information in a coherent way, enabling a clearer understand-
ing of the policy process, thereby speeding up the policy decision-making process and shortening the time for a 
malaria vaccine to become available.
© 2016 Romore et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
When a decision is made to adopt and implement a new 
health intervention in low and middle income countries 
(LMICs), it often takes years or decades before the ben-
efits of the new interventions are realized [1–5]. Thus, 
as new interventions become available, there is a need 
to improve understanding of the policy making process, 
as it applies to technology adoption and implementa-
tion [5–13]. The evidence-based information is needed 
in order to plan appropriately, set priority and choose 
from amongst the available alternatives [14, 15]. Lack of 
evidence-based information and framework could slow 
down the decision-making process and the process of 
rolling out new interventions [14, 15]. Frameworks have 
been useful for identifying relationships among the ele-
ments that guide and inform health policy processes [16]. 
In Tanzania, the decision-making process for adopting 
malaria interventions and new vaccines in general takes 
years, involving several processes before getting approval 
for use by the Ministry of Health and Social Welfare 
(MOHSW). In the case of the proposed introduction 
of malaria vaccines in Tanzania, a specific framework 
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for decision-making will speed up the administrative 
process and shorten the time until the vaccine is made 
available to the target population. This study adapted a 
policy framework to inform policy process for introduc-
ing malaria vaccine in Tanzania, to be able to distil les-
sons learnt that will also serve to guide malaria vaccine 
policy formulation and implementation.
Methods
Adapting a policy framework
A policy framework [17] highlights ways of understand-
ing policy processes based on four elements namely 
policy content, context, actors and processes involved in 
making and implementing policy [17] (Fig. 1). The policy 
framework analyses two elements; contextual (promot-
ing and barriers factors) and process influencing the 
decision-making process in order to establish a mecha-
nism that will facilitate a timely roll-out of the malaria 
vaccine RTS,S in Tanzania. It is important to analyse 
the ideal policy processes in assessing policy options 
for introducing new interventions and their subsequent 
adoption. For this case, the steps involved in the process 
to adopt policy decisions of malaria treatment policy 
change interventions in Tanzania was used. Several find-
ings confirmed the importance of a careful assessment 
of the policy process which will facilitate the reform or 
policy change [18–20]. Also; several studies have identi-
fied the importance of barriers in policy decision making 
[21]. Immunization and Vaccine Development (IVD) is 
the key actor as malaria vaccine is expected to be deliv-
ered through IVD programme and implemented at facil-
ity level by health care providers in both private and 
public facilities.
Study population
A sample of 20 key informants at the national level was 
assessed between July and August 2012. Participant cat-
egories included: international donors and public health 
stakeholders [the US Agency for International Develop-
ment, the President’s Malaria Initiative, the World Health 
Organization (WHO), the United Nations Children fund, 
the Centers for Disease Control and Prevention; national 
and political institutions (Legislature, Members of Par-
liament); public health officials (Ministry of Health and 
Social Welfare); programme managers of the National 
Malaria Control Programme, the Expanded Programme 
on Immunization]; regulatory authorities [Tanzania 
Food and Drug Authority; Ministry of Finance and Eco-
nomic Affairs], and professional organizations, academia 
and research institutions [National Institute for Medi-
cal Research, Ifakara Health Institute, African Malaria 
Network Trust and Tanzania Commission for Science 
and Technology. Purposeful sample of key informants 
were selected based on their knowledge and involvement 
in the process of changing malaria treatment policy in 
Tanzania. Interviews were open ended, with questions 
that aimed to analyse the existing policy process for new 
malaria interventions in Tanzania and to draw out les-
sons learned that could be applied to the forthcoming 
malaria vaccine policy adoption and implementation 
process.
Data collection
The face-to-face semi-structured interviews began by 
soliciting verbal informed consent and permission to 
record the interviews. Interviews lasted between 40 
and 60  min, depending on the level of detail offered by 
informants.
Data analysis
Interview notes were transcribed with the aid of record-
ings was uploaded and imported into MAXQDA 11 soft-
ware for coding based on the themes derived from the 
interviews related to content, context, process and actors 
involved in the policy process. Interviews were analysed 
thematically to understand the experiences of different 
stakeholders and to describe policy change processes. 
The Policy Analysis Framework was used to illustrate and 
interpret results.
The study protocol and interview guides were submit-
ted and approved by the Institutional Review Board at 
the Ifakara Health Institute.
Results
Ideal policy process
In Tanzania, the process of making policy decisions 
for the introduction of malaria interventions involves 
several steps. Interviewed participants highlighted the 
steps as follows: (i) reviewing the available evidence 
from different studies with consistent results and epi-
demiological data; (ii) considering the availability of Fig. 1 Policy Analysis Framework. Individuals, Groups, Organization
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alternative interventions to replace the failing interven-
tion, including the cost of the new intervention; (iii) 
forming a task force or technical groups composed of 
doctors and bilateral and multilateral partners to get 
additional scientific inputs and correctly package the 
evidence in language that can be easily understood by 
policy makers; (iv) getting feedback from the National 
Malaria Advisory Committee (NMAC), a technical 
body with the mandate to review technical evidence 
before it is made available to policy makers at the next 
level; (v) presenting scientific evidence to the National 
Malaria Control Program Manager to convince him of 
the need for the new intervention (NMCP is the secre-
tariat to the NMAC). The NMCP secretariat prepares a 
brief summary, which, together with the recommenda-
tions from the NMAC, are presented to the Director of 
preventive services and to the Chief Medical Officer of 
the MOHSW; (vi) the Director of Preventive Services 
and the CMO present the findings to the MOHSW 
Senior Management team to get their buy-in, endorse-
ment and approval for implementation. Normally this 
meeting would be held in the presence of the NMCP 
secretariat. The MOHSW Senior Management team 
comprises all Directorates (the Permanent Secretary, 
Director of Preventive services, Director of Curative 
Services, Chief Medical Officer, Director of Policy and 
Planning, Director of Human Resources and Director of 
Quality Assurance).
Context
The analysis of the context in which malaria policy deci-
sions are made yielded various themes. Themes were 
broadly categorized into one of two major areas, promot-
ing and barriers factors.
Promoting factors
According to interview participants, the major fac-
tors influencing the policy process for both malaria 
interventions:
Epidemiological and intervention characteristics
The WHO recommends that policy decisions for intro-
ducing new interventions be based on established evi-
dence of the epidemiology and burden of disease and on 
the safety, effectiveness and efficacy of the specific inter-
vention to prevent the target disease.
The interventions should be of high quality but the 
question of how MOHSW can ensure quality assurance 
for new interventions remains open. “We need to set cri-
teria for quality assurance, which we don’t have yet; the 
criteria to accept or not to accept the new interventions, 
which we do not have yet. It is an important observation 
you have noted”. (“MOHSW stakeholder”).
Country experiences of malaria treatment policy change
“Mapping the country and looking at decisions 
adopted in neighbouring countries with similar set-
tings, such as Kenya, Botswana, and Malawi, can 
influence policy decision outcomes”. In those coun-
tries, sulfadoxine-pyrimethamine has replaced chlo-
roquine as the first-line drug and they have already 
had to revise their national drug policy guidelines, 
accordingly (“NMCP stakeholder”).
Presentation and dissemination of evidence
Technical groups translate the evidence in a manner 
that is digestible and understandable to policy-makers. 
The groups include the Medical Association of Doctors, 
bilateral and multilateral partners, and scientific bodies. 
There are lessons to be learned from past experiences. A 
scientific package was developed at the time that treat-
ment policy changed from sulfadoxine-pyrimethamine 
to artemisinin-based combination therapy. The pack-
age included operation and orientation knowledge, an 
analysis of the costs and cost effectiveness of the new 
intervention and scientific proof that validated the inter-
vention locally, in the field. When policy makers are well 
informed, they will get involved. The knowledge that the 
policy makers accumulate is important for adoption and 
approval decisions.
“You have to simplify the language and hit the mes-
sage about replacement of the intervention” (“Bilat-
eral & Multilateral partners stakeholders”).
“A package of the information reflects what you need 
to bring as a point of reference. The Prime Minister’s 
Office Local Government and Regional Administra-
tion (PMOLRAG) hire and fire employees, therefore 
packaging information brings those employees on 
board and gives them a policy level of understand-
ing” (“Bilateral & Multilateral partners stakehold-
ers”).
Coordination and harmonization of the process
Despite the increasing calls for coordination and mecha-
nisms to improve the effectiveness of development assis-
tance, aid remains predominantly short-term in duration, 
unpredictable, geographically or technologically tied, and 
highly fragmented. Greater harmonization and align-
ment of donor aid can, in conjunction with broader 
health financing reforms, improve the equity of health 
outcomes.
Significant and effective leadership is required to coor-
dinate and harmonize the various stakeholders with 
stakes in the process. It will entail harmonizing the 
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policy process, planning, resources distribution, moni-
toring and evaluation in collaboration with donors and 
other international stakeholders. The process gives the 
opportunity from the outset to mobilize donor funding 
and to demonstrate to the donors and other partners the 
operational and other costs related to the policy adop-
tion and implementation and to show that the policy is 
cost effective. When donors and partners are taken on 
board at the early stages of discussing the policy change, 
it gives an opportunity to strategies and leverage finan-
cial and technical support towards the aim, thereby 
increasing the chance that the policy decision in ques-
tion will be adopted (“Bilateral & Multilateral partners 
stakeholders”).
Use of international scientific evidence
The use of international scientific evidence adapted to 
the local context is important for informing related pol-
icy decisions. Availability of an international consultant 
introduces another perspective and helps to clarify scien-
tifically proven evidence, thereby increasing the chances 
that a policy decision and intervention will be adopted 
(“Bilateral & Multilateral partners stakeholders”).
Barriers factors
Interview respondents also identified factors that were 
barriers to decisions to adopt new malaria policy. These 
included:
Financial sustainability
The country cannot generate its own resources to sus-
tainably fund new interventions from the national 
budget. Inadequate recurrent budgets have led to a 
dependency on donor funding. Sustainability of financing 
interventions is a challenge once when the donors with-
draw their funding. For instance, there are inadequate 
funds for vaccine operations at national level; the govern-
ment contributes 5.4 % of costs of vaccines. Specifically, 
the government covers the full costs of BDG, Measles, 
OPV and TT, while co-funding DPT-HEPB-HIB vaccine 
(as reported by “EPI stakeholder”).
Competing health and other priorities
Given its limited resources, the government must choose 
from among competing health priorities and other 
national and local priorities. Scientific evidence should 
justify the need for new interventions and be ranked as a 
priority in the MOFEA agenda:
“It is important to understand why a particular 
intervention needs to be given priority, if there is 
treatment, prevention, larviciding, residual spraying 
and bed nets; all these are competing interventions, 
they are competing for donor funding and donors 
have their own interests in funding” — (“Member of 
Parliament stakeholder”).
Political will and bureaucratic procedures
“Any new intervention takes time (two to three 
years) to be understood and then accepted”. Thus, 
planning for new interventions should start early to 
explore opportunities for engaging the government 
and donors, to take them on board, and to advocate 
and lobby for adoption. This is especially important 
in the context of government allocations for the roll 
out of malaria interventions and vaccines (“Bilat-
eral & Multilateral partners stakeholders”).
Costs related to the adoption and implementations 
of interventions
All costs related to adopting and implementing inter-
ventions imply that large amounts of funds are spent on 
management activities rather than on actual implementa-
tion of interventions to achieve positive health outcomes 
(“NMCP Stakeholder”).
Supply and distribution
In some instances, global supply does not meet the 
demand for the malaria interventions, Interview 
respondents reported distribution issues arising from the 
logistics of transporting interventions from the manu-
facturer to the users. Other issues of concern include: 
whether the interventions need special transport and 
storage, how they are stored, availability of vehicles to 
facilitate transportation, and user-friendly packaging of 
vaccines to facilitate delivery. Another important element 
is training of health care personnel involved in vaccina-
tion to understand the intervention. New interventions 
require development and roll out of an appropriate train-
ing package for health facilities (“NMCP, Bilateral donor 
Stakeholders”).
Professional compliance with anti‑malarial drugs
Access barriers related to affordability of interventions 
and competence of providers indicate that health infra-
structure’s capacity must be increased so that clinicians 
comply with the recommended national policy and guide-
lines (“NMCP stakeholder”). These barriers are mostly 
influenced by: financial sustainability, competing priori-
ties, political will and bureaucratic procedures, cost, sup-
ply and distribution and lack of compliance by users and 
health providers of the new malaria treatment policy.
The following list represents what stakeholders per-
ceived were the most salient lessons learned. The 
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potential malaria vaccine is a first generation malaria 
vaccine with a high probability of success at the Phase 
III stage; it targets specific age groups of children and 
is given as a consolidated package with other IVD 
vaccines.
  • IVD has an established infrastructure which can 
potentially accommodate new vaccines;
  • Factors for consideration are programmatic issues 
needed for a new vaccine, cold chain, training health 
workers, cost of introduction, funding opportunities 
available for the vaccine [Global Alliance for Vac-
cines and Immunization (GAVI)].
Key concerns from the donor group and key questions 
generated
  • What are the operational costs of adding a new vac-
cine?
  • What are the potential sources of funding to deliver 
the vaccine?
  • How do you ensure supply meets demand for the 
vaccine?
  • How do you demonstrate operational and other costs 
to the donor partners?
Package and disseminate information about the malaria 
vaccine
  • Develop a package for the community who are users 
of the vaccine to let them understand exactly what 
the vaccine is capable of achieving. Involves train-
ings and use of different types of media to facilitate 
adverts and advocacy.
Lobbying and advocacy
  • Any new interventions takes time (2–3  years) to be 
understood and then accepted, thus lobbying for the 
malaria vaccine should start now
  • Advocacy should begin early enough as it takes time 
for people to understand and accept new interven-
tions. Planning early will be important for the vac-
cine’s success
  • Explore opportunities such as the development of 
new strategies (government and donors) in which 
to include the malaria vaccine. The vaccine should 
be understood as a complementary intervention to 
existing malaria control measures, such as insecti-
cide-treated nets, artemisinin-based combination 
therapy and diagnostics
  • Integrate malaria vaccine with other opportunities, 
such as child health day, malaria campaigns in gen-
eral, and use of advocacy avenues.
  • To secure enough funding and involve other stake-
holders.
Planning, financing and implementation
  • There should be adequate analysis of the vaccine sys-
tem in line with the introduction of the forthcoming 
malaria vaccine (storage, delivery, and packaging).
Integration and complementarity
  • Attention should be paid to the documents or guide-
lines to show how the vaccine relates to and comple-
ments other ongoing malaria interventions.
  • Consider options for delivery at primary levels using 
existing interventions, e.g. the delivery of a booster 
dose should be explored and documented in the 
implementation guidelines.
Involvement of front line implementers
  • Sensitization of health workers has to begin early 
enough to improve on motivation and any negativity 
projected from them to community.
  • Involvement of health workers can be done through 
several, small gestures. For example, holding meet-
ings between Council Health Management Teams 
(CHMTs) and health workers when they conduct 
supervision, informing and advising them to accept 
a new vaccine.
Continuity and sustainability
  • Have a clear plan of what the funding sources would 
be after GAVI support ends
  • Use opportunity to develop new health-related strat-
egies to include the vaccine so that it is considered in 
funding
  • Ensure that there will be enough production so that 
procurement will not be affected by low production.
Discussion
The framework method has been developed and used 
widely in many countries and to address a variety of 
health policy concerns [22]. The policy framework com-
bines the concepts of content, context, actors and process 
to understand the policy process and to plan for effective 
implementation of interventions [17]. A policy frame-
work in this study built on the literature and was based 
on experiences and observations of the policy process 
and the factors influencing policy decisions in Tanzania. 
It was used to organize information in a way that explains 
the drivers of policy change and to gauge understanding 
and lessons learnt from the introduction of new malaria 
interventions through policy change.
The framework is feasible and can be used in the Tan-
zanian context. Although Tanzania has not yet intro-
duced a malaria vaccine, the framework contributes to 
understanding a very complex and highly political sub-
ject—policy analysis. It assists in unpacking the national 
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level discussion, involving evidence-based information, 
stakeholders’ interactions and political commitment; fac-
tors that are all important for planning the forthcoming 
malaria vaccine. Promoting factors, such as safety and 
efficacy, WHO protocol and decisions adopted in other 
countries, such as Burkina Faso [23, 24], Ghana [25], 
Gabon [26], Malawi [27] and Kenya [28]. Harmonization 
of the policy process across departments and collabora-
tion between policy makers and scientists were identified 
in Burkina Faso [23] and Malawi [27]. The importance of 
technical assistance from the WHO and other interested 
donors was also identified in Burkina Faso [23], Gabon 
[26], Malawi [27] and Kenya [28]. Among the identified 
barriers were the lack of sustainable financing in Burkina 
Faso [24], Gabon [26] and Kenya [28]; and non-adher-
ence to treatment in Burkina Faso [24], Mozambique [29] 
and Kenya [28]. Effective communication supporting the 
correct use of medicines can counteract non-adherence 
and use of in-effective medicines [30, 31]. It can also be 
done through engaging the private sector and encourag-
ing hospitals and pharmacies to adhere to national guide-
lines [23].
Strength and limitation
The framework described the potential for introducing 
a malaria vaccine in the health system while critically 
observing policy formulation and implementation. The 
framework approach has its limitations. It highlights 
some information while minimizing or excluding oth-
ers [32], in order to focus on aspects that are relevant to 
the study context [33]. The framework may or may not 
be applicable to other low-income countries with similar 
contexts. Its applicability depends on whether the policy 
is appropriate to the needs of a specific country and is 
feasible in a low-resource settings [34].
Conclusion and recommendations
The framework is used at the national level, while over-
all policy recommendation of RTS,S vaccine is made at 
the global level. The framework can be used once the 
global policy recommendation is made. The framework 
is a comprehensive tool that enables one to unpack the 
factors surrounding the decision to introduce a potential 
malaria vaccine in Tanzania. Furthermore, the frame-
work provides an effective way to improve knowledge 
of the policy process and to inform the policy decision-
making process for new malaria interventions, gener-
ally, and for a forthcoming malaria vaccine, specifically. 
Lastly, the framework facilitates the synthesis of infor-
mation in a coherent way, enabling a clearer understand-
ing of the policy process, thereby speeding up the policy 
decision-making process and shortening the time until 
the forthcoming malaria vaccine becomes available. The 
framework is useful and applicable, still further valida-
tion is required.
The framework is appropriate and recommended 
for various settings depending on the steps involved in 
decision-making process and availability of contextual 
(promoting and barriers factors) information to inform 
the policy decision process, which also implies a need of 
study to understand those factors before a policy decision 
is made on RTS,S adoption. It can be useful as a step in 
the direction of research that supports better formulation 
and implementation of malaria interventions policies in 
Africa.
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